The Pharma Market Access Pricing and Reimbursement Confererence 2013

The conference will provide attendees with an opportunity to learn about the key developments impacting the future of pharmaceutical pricing and reimbursement, including:

The increasing importance of generating, collecting and analyzing reimbursement evidence early in product development and identifying points of differentiation of a product versus existing standards of care

The impact of Health Technology Assessments (HTAs) on both private and public payer reimbursement decisions
Coverage with Evidence Development (CED) and performance-based risk-sharing agreements, based on long-term outcomes

The importance of a well thought out, integrated market access strategy for new biopharmaceutical products cannot be overestimated in today’s healthcare environment. No longer is it sufficient for biopharmaceutical companies to only clear the three traditional market access hurdles of safety, efficacy and quality.

Today, the 4th hurdle, economic value is just as important a determinant in reimbursement decisions being made by both public and private payers. Clinical and economic value must now be placed at the center of all product development and commercialization activities.